Relevant bibliographies by topics / Rasburicase

Academic literature on the topic 'Rasburicase'

Author: Grafiati
Published: 10 December 2022
Last updated: 21 February 2023

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Contents

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Rasburicase.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Rasburicase"

1

&NA;. "Rasburicase." Reactions Weekly &NA;, no. 1186 (January 2008): 32. http://dx.doi.org/10.2165/00128415-200811860-00101.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

&NA;. "Rasburicase." Reactions Weekly &NA;, no. 1140 (February 2007): 19. http://dx.doi.org/10.2165/00128415-200711400-00067.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

&NA;. "Rasburicase." Reactions Weekly &NA;, no. 1367 (September 2011): 32. http://dx.doi.org/10.2165/00128415-201113670-00113.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

&NA;. "Rasburicase." Reactions Weekly &NA;, no. 1371 (October 2011): 33. http://dx.doi.org/10.2165/00128415-201113710-00123.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

&NA;. "Rasburicase." Reactions Weekly &NA;, no. 1209 (July 2008): 26–27. http://dx.doi.org/10.2165/00128415-200812090-00084.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

&NA;. "Rasburicase." Reactions Weekly &NA;, no. 1087 (February 2006): 24. http://dx.doi.org/10.2165/00128415-200610870-00081.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Oldfield, Vicki, and Caroline M. Perry. "Rasburicase." Drugs 66, no. 4 (2006): 529–45. http://dx.doi.org/10.2165/00003495-200666040-00008.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

&NA;. "Rasburicase." Reactions Weekly &NA;, no. 1284 (January 2010): 36–37. http://dx.doi.org/10.2165/00128415-201012840-00122.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

&NA;. "Rasburicase." Reactions Weekly &NA;, no. 1307 (June 2010): 39. http://dx.doi.org/10.2165/00128415-201013070-00126.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

&NA;. "Rasburicase." Reactions Weekly &NA;, no. 1024 (October 2004): 13. http://dx.doi.org/10.2165/00128415-200410240-00038.

Full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Dissertations / Theses on the topic "Rasburicase"

1

Fichera, Marco. "Opzioni terapeutiche per il trattamento della gotta e delle iperuricemie nell'anziano." Thesis, Universita' degli Studi di Catania, 2012. http://hdl.handle.net/10761/1262.

Full text
Abstract:
Opzioni terapeutiche per il trattamento della gotta e delle iperuricemie nellâ anziano. Abstract Gotta ed iperuricemia sono patologie strettamente correlate che interessano prevalentemente pazienti anziani, i quali presentano spesso comorbilità   associate come i disturbi cardiovascolari e lâ insufficienza renale. Si deve sottolineare che iperuricemia e gotta non sono sinonimi in quanto la prima non sempre à ¨ seguita o accompagnata dal quadro della gotta (artrite, tofi, nefropatia). Il disordine metabolico, sempre presente nella gotta, appare come causa necessaria ma non sufficiente per lo sviluppo di questa malattia, quindi il corretto inquadramento diagnostico prevede una divisione schematica del trattamento che include la terapia del disordine metabolico di base (iperuricemia idiopatica/secondaria) da un lato e la terapia degli attacchi acuti e della gotta cronica dallâ altro. Lâ utilizzo di FANS, corticosteroidi e colchicina finalizzato al trattamento dellâ artropatia gottosa deve essere integrato dal trattamento dellâ iperuricemia, che si avvale di numerose opzioni terapeutiche come i farmaci uricosurici (Probenecid; Sulfinpirazone; Benzbromarone; Losartan; Fenofibrato), i farmaci inibitori della xantino ossidasi (Allopurinolo; Ossipurinolo; Febuxostat), i farmaci urolitici (Urato ossidasi estrattiva; Saccharomyces cerevisiae; Rasburicase) e farmaci di altra natura come il Canakinumab, il Sevelamer e lâ Acacia confusa. Risulta dunque molto importante che attraverso la ricerca scientifica vengano individuate nuove molecole dotate di sempre maggiore efficacia e tollerabilità  .
Treatment options for gout and hyperuricemia in the elderly. Abstract Gout and hyperuricemic syndrome are strictly related, mainly affecting elderly patients often showing associated comorbility as cardiovascular disease and kidney impairment. It should be stressed that hyperuricemia and gout are not synonymous as the first is not always followed by gout (arthropathy, tophi, nephropathy). The metabolic disorder shown in gout looks as necessary cause although not sufficient for the development of disease; therefore the correct diagnosis takes in consideration treatment including both therapy of metabolic disorder (idiopathic/secondary hyperuricemia) and treatment of acute conditions as well as chronic gout. Use of NSAID, steroids and colchicine for treatment of gout arthropathy should be implemented with hyperuricemic therapy through several options as uricosuric drugs (Probenecid; Sulfinpirazone; Benzbromarone; Losartan; Fenofibrato), xantino-oxidase inhibitors (Allopurinol; Ossipurinol; Febuxostat), uricolitic drugs (Urate oxidase extract; Saccharomyces cerevisiae; Rasburicase) and others as Canakinumab, Sevelamer and Acacia confuse. It is therefore important scientific investigation in order to further investigate new preparations with increased efficacy and tolerability.
APA, Harvard, Vancouver, ISO, and other styles

Book chapters on the topic "Rasburicase"

1

Ronco, C., R. Bellomo, P. Inguaggiato, M. Bonello, V. Bordoni, G. Salvatori, V. D�Intini, and R. Ratanarat. "Rasburicase Therapy in Acute Hyperuricemic Renal Dysfunction." In Contributions to Nephrology, 158–65. Basel: KARGER, 2004. http://dx.doi.org/10.1159/000078884.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Ronco, Claudio, Paola Inguaggiato, Valeria Bordoni, Massimo De Cal, Monica Bonello, Emilios Andrikos, Yavuz Assuman, Ranishta Rattanarat, and Rinaldo Bellomo. "Rasburicase Therapy in Acute Hyperuricemia and Renal Dysfunction." In Contributions to Nephrology, 115–23. Basel: KARGER, 2004. http://dx.doi.org/10.1159/000082549.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Jeha, Sima, and Ching-Hon Pui. "Recombinant Urate Oxidase (Rasburicase) in the Prophylaxis and Treatment of Tumor Lysis Syndrome." In Contributions to Nephrology, 69–79. Basel: KARGER, 2004. http://dx.doi.org/10.1159/000082545.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

"Rasburicase." In Pediatric Injectable Drugs, 758–61. American Society of Health-System Pharmacists, 2018. http://dx.doi.org/10.37573/9781585285402.212.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

"Rasburicase." In Meyler's Side Effects of Drugs, 89–91. Elsevier, 2016. http://dx.doi.org/10.1016/b978-0-444-53717-1.00165-7.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

"Rasburicase." In Encyclopedia of Cancer, 3188. Berlin, Heidelberg: Springer Berlin Heidelberg, 2011. http://dx.doi.org/10.1007/978-3-642-16483-5_4957.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

"Rasburicase." In ASHP® Injectable Drug Information™, 1381. ASHP, 2021. http://dx.doi.org/10.37573/9781585286850.337.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Kisor, David F. "Chapter 20: Oncology: Rasburicase/G6PD Case." In Pharmacogenomics: Foundations, Competencies, and the Pharmacists’ Patient Care Process. 2215 Constitution Avenue, N.W. Washington, DC 20037-2985: American Pharmacists Association, 2020. http://dx.doi.org/10.21019/9781582123127.ch20.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Kisor, David F. "Chapter 21: Oncology: Rasburicase/G6PD Case." In Pharmacogenomics: Foundations, Competencies, and the Pharmacists’ Patient Care Process, 2nd Edition. Washington, DC: American Pharmacists Association, 2022. http://dx.doi.org/10.21019/9781582123844.ch21.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Ronco, Pierre, Frank Bridoux, and Arnaud Jaccard. "Renal involvement in plasma cell dyscrasias, immunoglobulin-based amyloidoses, and fibrillary glomerulopathies, lymphomas, and leukaemias." In Oxford Textbook of Medicine, edited by John D. Firth, 5016–27. Oxford University Press, 2020. http://dx.doi.org/10.1093/med/9780198746690.003.0495.

Full text
Abstract:
Plasma cell dyscrasias are characterized by uncontrolled proliferation of a single clone of B cells which is responsible for the secretion of a monoclonal immunoglobulin (Ig) or Ig subunit that can deposit in tissues. They can cause a wide range of renal diseases. Light-chain amyloidosis—renal presentation is usually with proteinuria, often progressing to nephrotic syndrome. A progressive decline in renal function may occur, leading finally to endstage renal failure. Diagnosis is made by the detection of monoclonal gammopathy and free light-chain excess in the serum (90% of cases), in combination with biopsy evidence of amyloid-forming light-chain deposits. Myeloma—renal failure is found at presentation in 20% of patients, occurs in 50% at some time, and is most commonly caused by cast nephropathy, with renal biopsy typically showing ‘fractured’ casts. Chemotherapy should be introduced promptly. Light-chain, light- and heavy-chain, and heavy-chain deposition disease—collectively known as monoclonal Ig deposition diseases, present with proteinuria and renal failure. Diagnosis is by renal biopsy. Treatment strategy is based on chemotherapy (bortezomib-based regimens) followed by autologous stem cell transplantation in selected cases. Fibrillary glomerulonephritis and immunotactoid glomerulopathy—usual presentation is with nephrotic syndrome, microscopic haematuria, and hypertension. Immunotactoid glomerulopathy usually responds to chemotherapy. Cryoglobulinaemia—type II (‘essential mixed’) may present with proteinuria, haematuria, hypertension, and gradually declining renal function, or with an acute nephritic picture. Renal biopsy typically reveals membranoproliferative glomerulonephritis with massive subendothelial deposits. Treatment involves antiviral agents and/or immunosuppression. Tumour lysis syndrome—a life-threatening metabolic emergency that occurs in patients with haemopathies with high cell turnover, mostly at the onset of chemotherapy. Treatment is based on saline diuresis (if possible), rasburicase, and haemodialysis (if required).
APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Rasburicase"

1

Alexander, K. R., and O. Nadeem. "Acquired Methemoglobinemia Secondary to Rasburicase." In American Thoracic Society 2022 International Conference, May 13-18, 2022 - San Francisco, CA. American Thoracic Society, 2022. http://dx.doi.org/10.1164/ajrccm-conference.2022.205.1_meetingabstracts.a1563.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Christmas, Alex, Elizabeth Henderson, and Edgar Brincat. "294 Evaluation of rasburicase use within the paediatric intensive care unit." In RCPCH Conference Singapore. BMJ Publishing Group Ltd, 2021. http://dx.doi.org/10.1136/bmjpo-2021-rcpch.163.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Raru, Y., M. Abouzid, J. Parsons, and F. M. Zeid. "Rasburicase Induced Severe Hemolysis and Methemoglobinemia in a Caucasian Patient Complicated by Acute Renal Failure and ARDS." In American Thoracic Society 2019 International Conference, May 17-22, 2019 - Dallas, TX. American Thoracic Society, 2019. http://dx.doi.org/10.1164/ajrccm-conference.2019.199.1_meetingabstracts.a6548.

Full text
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the extended bibliographies on the topic 'Rasburicase' for particular source types:
Journal articles
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography